Log in

NASDAQ:CAPRCapricor Therapeutics Stock Price, Forecast & News

$4.43
-0.04 (-0.89 %)
(As of 07/8/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.36
Now: $4.43
$4.56
50-Day Range
$4.28
MA: $4.79
$5.40
52-Week Range
$0.88
Now: $4.43
$11.08
Volume366,100 shs
Average Volume3.23 million shs
Market Capitalization$63.19 million
P/E RatioN/A
Dividend YieldN/A
Beta6.83
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Read More
Capricor Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CAPR
CUSIPN/A
Phone310-358-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1 million
Book Value$1.31 per share

Profitability

Net Income$-7,640,000.00
Net Margins-750.83%

Miscellaneous

EmployeesN/A
Market Cap$63.19 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive CAPR News and Ratings via Email

Sign-up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.

Capricor Therapeutics (NASDAQ:CAPR) Frequently Asked Questions

How has Capricor Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Capricor Therapeutics' stock was trading at $1.0050 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CAPR stock has increased by 340.8% and is now trading at $4.43. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Capricor Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Capricor Therapeutics.

When is Capricor Therapeutics' next earnings date?

Capricor Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Capricor Therapeutics.

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics Inc (NASDAQ:CAPR) issued its quarterly earnings results on Thursday, May, 14th. The biotechnology company reported ($0.30) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.33) by $0.03. The biotechnology company earned $0.19 million during the quarter, compared to the consensus estimate of $0.21 million. Capricor Therapeutics had a negative net margin of 750.83% and a negative return on equity of 128.89%. View Capricor Therapeutics' earnings history.

What price target have analysts set for CAPR?

2 brokerages have issued twelve-month price objectives for Capricor Therapeutics' stock. Their forecasts range from $9.00 to $12.00. On average, they anticipate Capricor Therapeutics' share price to reach $10.50 in the next twelve months. This suggests a possible upside of 137.0% from the stock's current price. View analysts' price targets for Capricor Therapeutics.

Has Capricor Therapeutics been receiving favorable news coverage?

News articles about CAPR stock have been trending negative on Thursday, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Capricor Therapeutics earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Capricor Therapeutics.

Who are some of Capricor Therapeutics' key competitors?

What other stocks do shareholders of Capricor Therapeutics own?

Who are Capricor Therapeutics' key executives?

Capricor Therapeutics' management team includes the following people:
  • Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
  • Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
  • Anthony Bergmann, Chief Financial Officer, Principal Accounting Officer (Age 32)
  • Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
  • Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
  • Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
  • Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
  • Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
  • Deborah Ascheim M.D., Chief Medical Officer
  • Joshua A. Kazam, Director (Age 40)

What is Capricor Therapeutics' stock symbol?

Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."

How do I buy shares of Capricor Therapeutics?

Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Capricor Therapeutics' stock price today?

One share of CAPR stock can currently be purchased for approximately $4.43.

How big of a company is Capricor Therapeutics?

Capricor Therapeutics has a market capitalization of $63.19 million and generates $1 million in revenue each year. The biotechnology company earns $-7,640,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis.

What is Capricor Therapeutics' official website?

The official website for Capricor Therapeutics is www.capricor.com.

How can I contact Capricor Therapeutics?

Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.